In a retrospective real-world study of 83 patients (of these, 74 patients received IO as monotherapy) with ALK-rearranged NSCLC who received IO from a multicenter electronic medical record-derived database, the mPFS of patients who received IO before ALK-TKI was 3.9 months, and that of patients who received IO after ALK-TKI was 1.5 months [55]. Here, ALK is linked to non-small cell lung carcinoma.